ICM
LEXX icon

Invenomic Capital Management’s Lexaria Bioscience LEXX Stock Holding History

Invenomic Capital Management’s Portfolio LEXX Stock Details LEXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$194K Sell
23,046
-6,441
-22% -$69.8K 0.01% 114
2026
Q1 		$345K Sell
29,487
-1,907
-6% -$20.8K 0.02% 146
2025
Q4 		$291K Sell
31,394
-419
-1% -$5.95K 0.01% 145
2025
Q3 		$455K Sell
31,813
-1,618
-5% -$23.5K 0.02% 141
2025
Q2 		$436K Sell
33,431
-3,232
-9% -$55.7K 0.02% 146
2025
Q1 		$940K Buy
36,663
+9,281
+34% +$236K 0.05% 166
2024
Q4 		$863K Sell
27,382
-4,336
-14% -$160K 0.04% 157
2024
Q3 		$1.45M Sell
31,718
-2,520
-7% -$120K 0.08% 140
2024
Q2 		$1.43M Buy
34,238
+2,687
+9% +$121K 0.07% 153
2024
Q1 		$1.72M Sell
31,551
-17,248
-35% -$659K 0.09% 130
2023
Q4 		$915K Sell
48,799
-2,156
-4% -$41.6K 0.04% 161
2023
Q3 		$764K Sell
50,955
-150
-0.3% -$2.06K 0.03% 143
2023
Q2 		$560K Buy
51,105
+19,565
+62% +$380K 0.03% 133
2023
Q1 		$1.29M Hold
31,540
– – 0.07% 134
2022
Q4 		$1.16M Hold
31,540
– – 0.08% 131
2022
Q3 		$1.16M Buy
31,540
+7,193
+30% +$307K 0.1% 136
2022
Q2 		$1.09M Hold
24,347
– – 0.08% 134
2022
Q1 		$1.06M Buy
24,347
+406
+2% +$23K 0.11% 133
2021
Q4 		$1.45M Buy
23,941
+446
+2% +$38.1K 0.31% 92
2021
Q3 		$2.21M Buy
23,495
+2,354
+11% +$226K 0.72% 46
2021
Q2 		$2.22M Buy
21,141
+1,401
+7% +$125K 0.53% 41
2021
Q1 		$1.66M Buy
+19,740
New +$1.73M 0.37% 53

Other funds holding LEXX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

Invenomic Capital Management's LEXX Position: Q2 2026 in Review

Invenomic Capital Management reduced its Lexaria Bioscience (LEXX) stake by 22% in Q2 2026, selling an estimated $69.8K and leaving 23,046 shares worth $194K. The position accounts for 0.01% of the portfolio, ranked #114.

Invenomic Capital Management first reported a position in LEXX in Q1 2021 and has held it in 22 quarters since. The position peaked at $2.22M in Q2 2021. 29 funds tracked by Wall St. Rank hold LEXX as of Q2 2026.

  • Invenomic Capital Management held 23,046 shares of Lexaria Bioscience worth $194K as of Q2 2026.
  • Invenomic Capital Management sold 6,441 Lexaria Bioscience shares in Q2 2026, an estimated $69.8K.
  • Lexaria Bioscience made up 0.01% of Invenomic Capital Management's portfolio in Q2 2026, its #114 holding.
  • Invenomic Capital Management first reported a position in Lexaria Bioscience in Q1 2021 and has held it in 22 quarters since.
  • Invenomic Capital Management's Lexaria Bioscience position peaked at $2.22M in Q2 2021.
  • 29 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q2 2026.

Based on Invenomic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.